October 31, 2019

MADISON, WI, USA, Oct 31, 2019 – Invenra Inc. announced that it has expanded its collaboration with Exelixis, Inc. (Nasdaq: EXEL). Exelixis and Invenra had entered into a collaboration on May 2nd, 2018 to discover and develop multispecific antibodies...

January 31, 2019

Madison, WI.  Jan 31, 2019 – Invenra and WARF (Wisconsin Alumni Research Foundation) today announced they have entered into a collaboration to discover and develop a bispecific antibody therapeutic for the treatment of neuroblastoma, a cancer that is...

October 17, 2018

MADISON, Wis. – October 17, 2018 – Invenra, an antibody drug discovery and development company with novel multispecific platforms and product candidates, announced the close of a $7M Series B financing round. The financing will be used to expand the...

May 2, 2018

̶ Companies will partner to advance multispecific antibodies in up to seven discrete projects, including one program against an undisclosed target currently in lead selection –

̶ Exelixis’ expansion into biologics builds upon history of success in the...

September 26, 2017

MADISON, WI – September 26, 2017 – Invenra is pleased to announce the addition of Dr. Paul Sondel in the role of Chief Medical Advisor (Volunteer). Dr. Paul Sondel [MD- Harvard Medical School, and PhD in Genetics– University of Wisconsin-Madison (UW)...

Please reload


Invenra Announces Expansion of Collaboration with Exelixis

October 31, 2019

Please reload

Please reload




There are no items in this list

Please reload


505 South Rosa Road; Suite 235, Madison, WI 53719       info@invenra.com  |   608.441.8319

connect with us
  • Twitter - Black Circle
  • LinkedIn - Black Circle

© 2018 Invenra, Inc. All Rights Reserved.